HAGAR
Tel Aviv, Israel· Est.
HAGAR delivers a non‑invasive RF‑based CGM platform for accurate, real‑time glucose monitoring.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $21.1M
AI Company Overview
HAGAR delivers a non‑invasive RF‑based CGM platform for accurate, real‑time glucose monitoring.
Diabetes
Technology Platform
Low‑power radio‑frequency (RF) wave sensor combined with AI signal processing to non‑invasively measure blood glucose in real time.
Opportunities
Capitalizing on the growing demand for painless CGM solutions and leveraging FDA Breakthrough designation to accelerate market entry, HAGAR can capture a niche segment of diabetes patients seeking non‑invasive monitoring.
Risk Factors
Regulatory approval timelines, demonstration of long‑term safety and accuracy, and competition from established CGM manufacturers could delay commercialization.
Competitive Landscape
Key competitors include Abbott, Dexcom, and Medtronic, which offer invasive or minimally invasive CGM devices; HAGAR differentiates itself through true non‑invasive RF measurement and AI‑enhanced accuracy.